Author(s) Deak ST

Journal Journal of vascular surgery. Venous and lymphatic disorders. Date of publication 2022 Sep 1;volume 10(5):999-1006.e2.

Abstract 1. J Vasc Surg Venous Lymphat Disord. 2022 Sep;10(5):999-1006.e2. doi: 10.1016/j.jvsv.2021.11.007. Epub 2021 Dec 24. Treatment of superficial venous insufficiency in a large patient cohort with retrograde administration of ultrasound-guided polidocanol endovenous microfoam versus endovenous laser ablation. Deak ST(1). Author information: (1)Deak Vein NJ Clinic, Somerset, NJ. Electronic address: stdeak@gmail.com. OBJECTIVE: To evaluate outcomes among symptomatic patients with superficial chronic venous insufficiency treated with retrograde ultrasound-guided polidocanol endovenous microfoam 1% (PEM) or endovenous laser ablation (EVLA). METHODS: This study is a retrospective chart review from a single vein center between October 2013 and June 2019. Procedures were performed on 1070 patients with Clinical, Etiologic, Anatomic, and Pathophysiologic class 2 to 6 disease and symptomatic superficial venous reflux of the great saphenous vein or anterior accessory saphenous vein. RESULTS: PEM was used for 550 procedures and patients were followed for 43 ± 13 months; EVLA was used for 520 procedures and patients were followed for 57 ± 18 months. After complete treatment, the elimination of reflux was documented in 93.5% (514/550) and 92.8% (482/520) of the PEM and EVLA procedures, respectively. During the follow-up period, 18% of patients treated with EVLA returned for additional treatment to address residual symptoms in the affected leg. In C6 patients treated with PEM, 69% of ulcers (11/16) healed in less than 1 month, compared with 5% of patients (1/21) treated with EVLA. In C4 patients with lesions, resolution of spontaneous bleeding was 100% in both groups. There were no neurological or cardiac adverse events in the PEM group. Minor complications included asymptomatic deep vein thrombosis (0.5%), one common femoral vein thrombus extension, and superficial venous thrombosis (4%) in the PEM group and asymptomatic deep vein thrombosis (0.8%) and two endovenous heat-induced thromboses in the EVLA group. CONCLUSIONS: PEM is comparable in safety and efficacy with EVLA for the treatment of saphenous reflux and associated symptoms. PEM was an effective intervention for most patients with C6 disease. Closure rates in both groups were maintained 36 months after treatment. Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. DOI: 10.1016/j.jvsv.2021.11.007 PMID: 34958977 [Indexed for MEDLINE]

Source ID (e.g. PMID): 34958977